Direct Conversion from Seroquel 100 mg to Seroquel XR 200 mg
Yes, a patient on quetiapine immediate-release 100 mg twice daily (total 200 mg/day) can be directly switched to quetiapine XR 200 mg once daily. The FDA label explicitly states that patients on immediate-release formulation may be switched to the extended-release formulation at the equivalent total daily dose taken once daily 1.
Conversion Strategy
The 1:1 Total Daily Dose Rule
- Calculate the total daily dose of immediate-release quetiapine (in this case: 100 mg × 2 = 200 mg/day)
- Switch directly to the same total daily dose of XR formulation given once daily (200 mg XR once daily)
- Timing: Administer XR in the evening to minimize daytime sedation 2
Important Caveats from FDA Labeling
The FDA label notes that "individual dosage adjustments may be necessary" after conversion 1. This means:
- Monitor closely during the first 1-2 weeks post-conversion for:
- Breakthrough symptoms (may need dose increase)
- Excessive sedation (may need dose decrease)
- Changes in side effect profile
Why This Conversion Works
Pharmacokinetic equivalence: Once-daily quetiapine XR produces similar AUC (total drug exposure) and minimum plasma concentration (Cmin) compared to the equivalent total daily dose of IR given twice daily, though with a slightly lower peak concentration (Cmax) 2. This pharmacokinetic profile maintains therapeutic efficacy while potentially reducing peak-related side effects.
Clinical evidence: Multiple studies confirm that stable patients switched from IR to equivalent-dose XR maintain clinical stability without loss of efficacy or tolerability issues 3, 4, 5, 6.
Advantages of XR Over IR
- Reduced daytime sedation: XR formulation shows significantly lower intensity of sedation during daytime hours compared to IR (p<0.0008 to p<0.0009) 6
- Improved patient satisfaction: Patients report better overall treatment satisfaction (p=0.0417) and milder side effects (p=0.0035) with XR 6
- Once-daily dosing: May improve adherence compared to twice-daily regimen 7, 4
- Less variable drug levels: XR exhibits less variable steady-state exposure (coefficient of variation 39.2% vs 51.2% for IR) 2
Practical Implementation
- Make the switch abruptly: No cross-titration needed when converting from IR to XR at equivalent doses
- Administer XR in the evening: Preferably without food or with a light meal (avoid high-fat meals which increase absorption) 2
- Monitor for 2 weeks: Assess symptom control and tolerability
- Adjust if needed: If symptoms emerge or side effects are problematic, individual dose adjustments are appropriate within the therapeutic range
Special Populations Requiring Caution
While the 1:1 conversion applies broadly, slower titration and lower target doses should be considered in 1:
- Elderly patients (start XR at 50 mg/day, increase by 50 mg increments)
- Hepatically impaired patients (start at 50 mg/day)
- Patients on CYP3A4 inhibitors (reduce dose to one-sixth)
- Patients on CYP3A4 inducers (may need up to 5-fold dose increase)
Bottom line: The conversion from 100 mg IR twice daily to 200 mg XR once daily is FDA-approved, pharmacokinetically sound, and clinically validated, though individual monitoring and adjustment may be needed.